Tripti Kumari
Research Subjects
Research Interests
Tripti Kumari has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
- Jaehyung Cho
Division of Hematology, Department of Medicine, Washington University School of Medicine, St Louis, MO, USA
2 shared publications - Ahmed Diab
Department of Medicine, Washington University School of Medicine, St Louis, Missouri, USA
1 shared publication - Ali Javaheri
Washington University School of Medicine, St. Louis, MO (D.L.M., A.J.).
1 shared publication - Amanda Girardi
Washington University School of Medicine - CME, Saint Louis, MO
1 shared publication - Amber Olson
Division of Hematology, Department of Medicine, Washington University School of Medicine, St. Louis, MO 2
1 shared publication - Andrew Barazia
Department of Pharmacology, University of Illinois at Chicago College of Medicine, Chicago, IL 1
1 shared publication
Latest Publications
- 28 April 2022
- Published by Elsevier in Journal of Cardiac Failure
- Vol. 28 (5) , S3
Dapagliflozin Improves Endothelial Integrity And Cardiac Loading Through A Sphingosine-1-phosphate / Apolipoprotein M Dependent Pathway
- 28 April 2022
- Published by Elsevier in Journal of Cardiac Failure
- Vol. 28 (5) , S3
Dapagliflozin Improves Endothelial Integrity And Cardiac Loading Through A Sphingosine-1-phosphate / Apolipoprotein M Dependent Pathway
- Open Access
- 9 November 2021
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 219 (1)
Neutrophil DREAM promotes neutrophil recruitment in vascular inflammation
The interaction between neutrophils and endothelial cells is critical for the pathogenesis of vascular inflammation. However, the regulation of neutrophil adhesive function remains not fully understood. Intravital microscopy demonstrates that neutrophil DREAM promotes neutrophil recruitment to sites of inflammation induced by TNF-α but not MIP-2 or fMLP. We observe that neutrophil DREAM represses expression of A20, a negative regulator of NF-κB activity, and enhances expression of pro-inflammatory molecules and phosphorylation of IκB kinase (IKK) after TNF-α stimulation. Studies using genetic and pharmacologic approaches reveal that DREAM deficiency and IKKβ inhibition significantly diminish the ligand-binding activity of β2 integrins in TNF-α–stimulated neutrophils or neutrophil-like HL-60 cells. Neutrophil DREAM promotes degranulation through IKKβ-mediated SNAP-23 phosphorylation. Using sickle cell disease mice lacking DREAM, we show that hematopoietic DREAM promotes vaso-occlusive events in microvessels following TNF-α challenge. Our study provides evidence that targeting DREAM might be a novel therapeutic strategy to reduce excessive neutrophil recruitment in inflammatory diseases.
- 9 November 2021
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 219 (1)
Open AccessNeutrophil DREAM promotes neutrophil recruitment in vascular inflammation
The interaction between neutrophils and endothelial cells is critical for the pathogenesis of vascular inflammation. However, the regulation of neutrophil adhesive function remains not fully understood. Intravital microscopy demonstrates that neutrophil DREAM promotes neutrophil recruitment to sites of inflammation induced by TNF-α but not MIP-2 or fMLP. We observe that neutrophil DREAM represses expression of A20, a negative regulator of NF-κB activity, and enhances expression of pro-inflammatory molecules and phosphorylation of IκB kinase (IKK) after TNF-α stimulation. Studies using genetic and pharmacologic approaches reveal that DREAM deficiency and IKKβ inhibition significantly diminish the ligand-binding activity of β2 integrins in TNF-α–stimulated neutrophils or neutrophil-like HL-60 cells. Neutrophil DREAM promotes degranulation through IKKβ-mediated SNAP-23 phosphorylation. Using sickle cell disease mice lacking DREAM, we show that hematopoietic DREAM promotes vaso-occlusive events in microvessels following TNF-α challenge. Our study provides evidence that targeting DREAM might be a novel therapeutic strategy to reduce excessive neutrophil recruitment in inflammatory diseases.